CRISPR/Cas9: A revolutionary genome editing tool for human cancers treatment

被引:16
作者
Akram, Fatima [1 ]
ul Haq, Ikram [1 ,2 ]
Sahreen, Sania [1 ]
Nasir, Narmeen [1 ]
Naseem, Waqas [1 ]
Imitaz, Memoona [1 ]
Aqeel, Amna [1 ]
机构
[1] Govt Coll Univ, Inst Ind Biotechnol, Lahore 54000, Pakistan
[2] Pakistan Acad Sci, Islamabad, Pakistan
关键词
CRISPR; Cas9; cancer; diagnosis; gene editing; immunotherapy; ENDOTHELIAL GROWTH-FACTOR; METASTATIC PROSTATE-CANCER; CELL LUNG-CANCER; CAR-T-CELLS; COLORECTAL-CANCER; BREAST-CANCER; IMMUNE-SYSTEM; FREE SURVIVAL; GENE; CRISPR-CAS9;
D O I
10.1177/15330338221132078
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cancer is a genetic disease stemming from genetic and epigenetic mutations and is the second most common cause of death across the globe. Clustered regularly interspaced short palindromic repeats (CRISPR) is an emerging gene-editing tool, acting as a defense system in bacteria and archaea. CRISPR/Cas9 technology holds immense potential in cancer diagnosis and treatment and has been utilized to develop cancer disease models such as medulloblastoma and glioblastoma mice models. In diagnostics, CRISPR can be used to quickly and efficiently detect genes involved in various cancer development, proliferation, metastasis, and drug resistance. CRISPR/Cas9 mediated cancer immunotherapy is a well-known treatment option after surgery, chemotherapy, and radiation therapy. It has marked a turning point in cancer treatment. However, despite its advantages and tremendous potential, there are many challenges such as off-target effects, editing efficiency of CRISPR/Cas9, efficient delivery of CRISPR/Cas9 components into the target cells and tissues, and low efficiency of HDR, which are some of the main issues and need further research and development for completely clinical application of this novel gene editing tool. Here, we present a CRISPR/Cas9 mediated cancer treatment method, its role and applications in various cancer treatments, its challenges, and possible solution to counter these challenges.
引用
收藏
页数:16
相关论文
共 162 条
[31]   CRISPR gene editing tested in a person [J].
Cyranoski, David .
NATURE, 2016, 539 (7630) :479-479
[32]   The Growth and Aggressive Behavior of Human Osteosarcoma Is Regulated by a CaMKII-Controlled Autocrine VEGF Signaling Mechanism [J].
Daft, Paul G. ;
Yang, Yang ;
Napierala, Dobrawa ;
Zayzafoon, Majd .
PLOS ONE, 2015, 10 (04)
[33]   Cytokines in cancer pathogenesis and cancer therapy [J].
Dranoff, G .
NATURE REVIEWS CANCER, 2004, 4 (01) :11-22
[34]   Sequential cancer mutations in cultured human intestinal stem cells [J].
Drost, Jarno ;
van Jaarsveld, Richard H. ;
Ponsioen, Bas ;
Zimberlin, Cheryl ;
van Boxtel, Ruben ;
Buijs, Arjan ;
Sachs, Norman ;
Overmeer, Rene M. ;
Offerhaus, G. Johan ;
Begthel, Harry ;
Korving, Jeroen ;
van de Wetering, Marc ;
Schwank, Gerald ;
Logtenberg, Meike ;
Cuppen, Edwin ;
Snippert, Hugo J. ;
Medema, Jan Paul ;
Kops, Geert J. P. L. ;
Clevers, Hans .
NATURE, 2015, 521 (7550) :43-U329
[35]   Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection [J].
Eyquem, Justin ;
Mansilla-Soto, Jorge ;
Giavridis, Theodoros ;
van der Stegen, Sjoukje J. C. ;
Hamieh, Mohamad ;
Cunanan, Kristen M. ;
Odak, Ashlesha ;
Goenen, Mithat ;
Sadelain, Michel .
NATURE, 2017, 543 (7643) :113-+
[36]   The mannose receptor LY75 (DEC205/CD205) modulates cellular phenotype and metastatic potential of ovarian cancer cells [J].
Faddaoui, Adnen ;
Bachvarova, Magdalena ;
Plante, Marie ;
Gregoire, Jean ;
Renaud, Marie-Claude ;
Sebastianelli, Alexandra ;
Gobeil, Stephane ;
Morin, Chantale ;
Macdonald, Elizabeth ;
Vanderhyden, Barbara ;
Bachvarov, Dimcho .
ONCOTARGET, 2016, 7 (12) :14125-14142
[37]   CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy [J].
Fry, Terry J. ;
Shah, Nirali N. ;
Orentas, Rimas J. ;
Stetler-Stevenson, Maryalice ;
Yuan, Constance M. ;
Ramakrishna, Sneha ;
Wolters, Pamela ;
Martin, Staci ;
Delbrook, Cindy ;
Yates, Bonnie ;
Shalabi, Haneen ;
Fountaine, Thomas J. ;
Shern, Jack F. ;
Majzner, Robbie G. ;
Stroncek, David F. ;
Sabatino, Marianna ;
Feng, Yang ;
Dimitrov, Dimiter S. ;
Zhang, Ling ;
Sang Nguyen ;
Qin, Haiying ;
Dropulic, Boro ;
Lee, Daniel W. ;
Mackall, Crystal L. .
NATURE MEDICINE, 2018, 24 (01) :20-+
[38]   The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA [J].
Garneau, Josiane E. ;
Dupuis, Marie-Eve ;
Villion, Manuela ;
Romero, Dennis A. ;
Barrangou, Rodolphe ;
Boyaval, Patrick ;
Fremaux, Christophe ;
Horvath, Philippe ;
Magadan, Alfonso H. ;
Moineau, Sylvain .
NATURE, 2010, 468 (7320) :67-71
[39]   CRISPR/Cas9 revitalizes adoptive T-cell therapy for cancer immunotherapy [J].
Ghaffari, Sasan ;
Khalili, Nastaran ;
Rezaei, Nima .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2021, 40 (01)
[40]   CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe [J].
Gilham, David E. ;
Debets, Reno ;
Pule, Martin ;
Hawkins, Robert E. ;
Abken, Hinrich .
TRENDS IN MOLECULAR MEDICINE, 2012, 18 (07) :377-384